ReviewNature reviews. Urology2021
Molecular determinants of disease severity in urinary tract infection.
Review in Nature reviews. Urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 citations in OpenAlex.
- Transposon-insertion sequencing reveals NlpD as a vulnerability in intracellular survival and pathogenesis of Salmonella 4,[5],12:i:.PLoS pathogens · 2026Article
- Urogenital immune signatures are associated with birth outcomes after maternal urinary tract infection.Science translational medicine · 2026Article
- How Does Biological Sex Impact Mucosal Bacterial Infection? Mucosal Defenses and Bacterial Detection.Immunological reviews · 2026Review
- Distribution of acquired carbapenemase genes among uropathogenic Escherichia coli.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Etiology, incidence and clinical manifestations of urinary tract infections in evolving population of kidney transplant recipients - a single center 10-year retrospective analysis.Frontiers in cellular and infection microbiology · 2026Article
- Efficacy of hc-tNGS for pathogen identification for pediatric cUTIs: a real-world observational study.Frontiers in cellular and infection microbiology · 2026Observational
- Decoding epithelial-immune cell crosstalk in uropathogenicFrontiers in microbiology · 2026Review
- Trained Immunity in Bladder ILC3s Enhances Mucosal Defense Against Recurrent Urinary Tract Infections.Biomedicines · 2025Article
- Modulating the gut-bladder axis: fecal transplantation protects antibiotic-treated mice from E. coli cystitis via the Ahr/Prg4 pathway.Microbiome · 2025Article
- CAUTIon - not all UTIs are the same.Nature reviews. Urology · 2025Review
- Regional Burden of Urinary Tract Infection, Its Aetiologies, and Antibiotic Resistance Patterns, 2020-2023: A Retrospective Study.Health science reports · 2025Article
- Metatranscriptomics-based metabolic modeling of patient-specific urinary microbiome during infection.NPJ biofilms and microbiomes · 2025Article
- High proportions of multidrug-resistant Klebsiella pneumoniae isolates in community-acquired infections, Brazil.Scientific reports · 2025Article
- Molecular analysis of acute pyelonephritis-excessive innate and attenuated adaptive immunity.Life science alliance · 2025Article
- Urinary tract infections: pathogenesis, host susceptibility and emerging therapeutics.Nature reviews. Microbiology · 2025Review
- Chronic urinary tract infections cause persistent microglial changes in a humanized ɑ-synuclein mouse model.Journal of Parkinson's disease · 2024Article
- Distinct maternofetal immune signatures delineate preterm birth onset following urinary tract infection.bioRxiv : the preprint server for biology · 2024Article
- Single-cell sequencing combined with spatial transcriptomics reveals that the IRF7 gene in M1 macrophages inhibits the occurrence of pancreatic cancer by regulating lipid metabolism-related mechanisms.Clinical and translational medicine · 2024Article
- MANNosylation of Mesoporous Silica Nanoparticles Modifies TLR4 Localization and NF-κB Translocation in T24 Bladder Cancer Cells.Advanced healthcare materials · 2024Article
- Polyvalent Bacterial Lysate with Potential Use to Treatment and Control of Recurrent Urinary Tract Infections.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common and lethal bacterial pathogens have co-evolved with the host. Pathogens are the aggressors, and the host immune system is responsible for the defence. However, immune responses can also become destructive, and excessive innate immune activation is a major cause of infection-associated morbidity, exemplified by symptomatic urinary tract infections (UTIs), which are caused, in part, by excessive innate immune activation. Severe kidney infections (acute pyelonephritis) are a major cause of morbidity and mortality, and painful infections of the urinary bladder (acute cystitis) can become debilitating in susceptible patients. Disease severity is controlled at specific innate immune checkpoints, and a detailed understanding of their functions is crucial for strategies to counter microbial aggression with novel treatment and prevention measures. One approach is the use of bacterial molecules that reprogramme the innate immune system, accelerating or inhibiting disease processes. A very different outcome is asymptomatic bacteriuria, defined by low host immune responsiveness to bacteria with attenuated virulence. This observation provides the rationale for immunomodulation as a new therapeutic tool to deliberately modify host susceptibility, control the host response and avoid severe disease. The power of innate immunity as an arbitrator of health and disease is also highly relevant for emerging pathogens, including the current COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.